TY - JOUR
T1 - Magnetoencephalography as a putative biomarker for Alzheimer's disease
AU - Zamrini, E.
AU - Maestu, F.
AU - Pekkonen, E.
AU - Funke, M.
AU - Makela, J.
AU - Riley, M.
AU - Bajo, R.
AU - Sudre, G.
AU - Fernandez, A.
AU - Castellanos, N.
AU - Del Pozo, F.
AU - Stam, C.J.
AU - van Dijk, B.W.
AU - Bagic, A.
AU - Becker, J.T.
PY - 2011
Y1 - 2011
N2 - Alzheimer's Disease (AD) is the most common dementia in the elderly and is estimated to affect tens of millions of people worldwide. AD is believed to have a prodromal stage lasting ten or more years. While amyloid deposits, tau filaments, and loss of brain cells are characteristics of the disease, the loss of dendritic spines and of synapses predate such changes. Popular preclinical detection strategies mainly involve cerebrospinal fluid biomarkers, magnetic resonance imaging, metabolic PET scans, and amyloid imaging. One strategy missing from this list involves neurophysiological measures, which might be more sensitive to detect alterations in brain function. The Magnetoencephalography International Consortium of Alzheimer's Disease arose out of the need to advance the use of Magnetoencephalography (MEG), as a tool in AD and pre-AD research. This paper presents a framework for using MEG in dementia research, and for short-term research priorities. Copyright © 2011 Edward Zamrini et al.
AB - Alzheimer's Disease (AD) is the most common dementia in the elderly and is estimated to affect tens of millions of people worldwide. AD is believed to have a prodromal stage lasting ten or more years. While amyloid deposits, tau filaments, and loss of brain cells are characteristics of the disease, the loss of dendritic spines and of synapses predate such changes. Popular preclinical detection strategies mainly involve cerebrospinal fluid biomarkers, magnetic resonance imaging, metabolic PET scans, and amyloid imaging. One strategy missing from this list involves neurophysiological measures, which might be more sensitive to detect alterations in brain function. The Magnetoencephalography International Consortium of Alzheimer's Disease arose out of the need to advance the use of Magnetoencephalography (MEG), as a tool in AD and pre-AD research. This paper presents a framework for using MEG in dementia research, and for short-term research priorities. Copyright © 2011 Edward Zamrini et al.
UR - https://www.scopus.com/pages/publications/79959261188
UR - https://www.scopus.com/inward/citedby.url?scp=79959261188&partnerID=8YFLogxK
U2 - 10.4061/2011/280289
DO - 10.4061/2011/280289
M3 - Article
SN - 2090-0252
VL - 2011
SP - 280289
JO - International Journal of Alzheimer's Disease
JF - International Journal of Alzheimer's Disease
ER -